임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

21건 표시

1/2상모집 예정· Myeloma Multiple
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
협력: 애브비, 사노피
상세 →NCT07600151
1/2상모집 예정· Acute Lymphoblastic Leukemia
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
협력: 애브비, 아스트라제네카
상세 →NCT07175415
1/2상모집 예정· Arthritis, Rheumatoid
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
리드: BMS
상세 →NCT07412704
1/2상모집 예정· Solid Tumors
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
리드: GSK
상세 →NCT07602855
1/2상모집 예정· High-Grade Glioma (HGG)
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
리드: 리제네론
상세 →NCT07567469
1/2상모집 예정· Hormone Receptor Positive
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
협력: 머크(MSD)
상세 →NCT07701941
1/2상모집 예정· JAK1 GOF
Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
협력: 애브비
상세 →NCT07670156
1/2상모집 예정· Ovarian Cancer
Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
협력: 리제네론
상세 →NCT07637851
1/2상모집 예정· Acute Lymphoblastic Leukemia
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
리드: 노바티스
상세 →NCT07387926
1/2상모집 예정· Primary Open Angle Glaucoma (POAG)
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
리드: 리제네론
상세 →NCT07675824
1/2상모집 예정· Relapsed or Refractory Multiple Myeloma
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
리드: 아스트라제네카
상세 →NCT07681596
1/2상모집 예정· HER2+ Metastatic Breast Cancer
Asciminib in HER2+ Breast Cancer Brain Metastases
협력: 노바티스
상세 →NCT07136428
1/2상모집 예정· Lymphoma, Non-Hodgkin
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
리드: GSK
상세 →NCT07607925
1/2상모집 예정· B-cell Acute Lymphoblastic Leukemia
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
협력: 암젠, 화이자
상세 →NCT07313852
1/2상모집 예정· Metastatic Castration-Resistant Prostate Cancer (mCRPC)
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
리드: 리제네론
상세 →NCT07594106
1/2상모집 예정· Recurrent Respiratory Papillomatosis (RRP)
Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*
협력: 머크(MSD)
상세 →NCT07339163
1/2상모집 예정· Glioma, Malignant
Niraparib and Temozolomide in Patients Glioblastoma
협력: GSK
상세 →NCT06258018
1/2상모집 예정· Sickle Cell Disease
Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
협력: 노바티스
상세 →NCT05469828
1/2상모집 예정· KRAS Mutation-Related Tumors
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
협력: 노바티스
상세 →NCT06456138
1/2상모집 예정· Breast Cancer
A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr
협력: GSK
상세 →NCT05519670
1/2상모집 예정· Multiple Myeloma
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
협력: GSK
상세 →NCT05581875

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.